Letrozole vs observation for HR positive breast cancer

Visit www.ecancer.org for more
Dr Zdenkowski (University of Newcastle, Newcastle, Australia) talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET.